Thrombospondin-1 and Transforming Growth Factor Beta-1 Upregulate Plasminogen Activator Inhibitor Type 1 in Pancreatic Cancer

Daniel Albo, David H. Berger, Jon Vogel, George P. Tuszynski

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Controlled degradation of the extracellular matrix by proteases is crucial in tumor cell invasion. We have shown that thrombospondin-1 (TSP-1), through activation of transforming growth factor beta-1 (TGF-β1), regulates the plasminogen/plasmin protease system in breast cancer. To determine whether this occurred in other epithelial neoplasms, we studied the role of TSP-1 and TGF-β1 in the regulation of the plasminogen/plasmin system in pancreatic cancer. ASPC-1 and COLO-357 pancreatic cancer cells were treated with TSP-1 or TGF-β1 at varying concentrations. The TSP-1 and TGF-β1-treated cells were also treated with either anti-TSP-1, anti-TSP-1 receptor, or anti-TGF-β1 antibodies. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) expression was determined by enzyme-linked immunosorbent assay. TSP-1 and TGF-β1 promoted a dose-dependent upregulation of ASPC-1 and COLO-357 PAI-1 expression. The TSP-1 effect could be blocked with anti-TSP-1 or anti-TGF-β1 antibodies. The TGF-β1 effect could be blocked only with anti-TGF-β1 antibody. Anti-TSP-1 receptor antibody blocked the TSP-1 effect on PAI-1 expression but had no effect on TGF-β1-mediated PAI-1 expression. Neither TSP-1 nor TGF-β1 had an effect on uPA production. We conclude that TSP-1, in a receptor-mediated process that involves the activation of TGF-β1, upregulates PAI-1 expression in pancreatic cancer without an effect on uPA production.

Original languageEnglish (US)
Pages (from-to)411-417
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume3
Issue number4
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Thrombospondin 1
Plasminogen Activator Inhibitor 1
Pancreatic Neoplasms
Transforming Growth Factor beta
Up-Regulation
Plasminogen Activators
Urokinase-Type Plasminogen Activator
CD36 Antigens
Antibodies
Plasminogen
Fibrinolysin
Peptide Hydrolases
Glandular and Epithelial Neoplasms
Extracellular Matrix

Keywords

  • Pancreatic neoplasms
  • Plasminogen activator inhibitor
  • Thrombospondin-1
  • Transforming growth factor beta-1
  • Urokinase plasminogen activator

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Thrombospondin-1 and Transforming Growth Factor Beta-1 Upregulate Plasminogen Activator Inhibitor Type 1 in Pancreatic Cancer. / Albo, Daniel; Berger, David H.; Vogel, Jon; Tuszynski, George P.

In: Journal of Gastrointestinal Surgery, Vol. 3, No. 4, 01.01.1999, p. 411-417.

Research output: Contribution to journalArticle

@article{fae70bddafd3476ca6359a26df001319,
title = "Thrombospondin-1 and Transforming Growth Factor Beta-1 Upregulate Plasminogen Activator Inhibitor Type 1 in Pancreatic Cancer",
abstract = "Controlled degradation of the extracellular matrix by proteases is crucial in tumor cell invasion. We have shown that thrombospondin-1 (TSP-1), through activation of transforming growth factor beta-1 (TGF-β1), regulates the plasminogen/plasmin protease system in breast cancer. To determine whether this occurred in other epithelial neoplasms, we studied the role of TSP-1 and TGF-β1 in the regulation of the plasminogen/plasmin system in pancreatic cancer. ASPC-1 and COLO-357 pancreatic cancer cells were treated with TSP-1 or TGF-β1 at varying concentrations. The TSP-1 and TGF-β1-treated cells were also treated with either anti-TSP-1, anti-TSP-1 receptor, or anti-TGF-β1 antibodies. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) expression was determined by enzyme-linked immunosorbent assay. TSP-1 and TGF-β1 promoted a dose-dependent upregulation of ASPC-1 and COLO-357 PAI-1 expression. The TSP-1 effect could be blocked with anti-TSP-1 or anti-TGF-β1 antibodies. The TGF-β1 effect could be blocked only with anti-TGF-β1 antibody. Anti-TSP-1 receptor antibody blocked the TSP-1 effect on PAI-1 expression but had no effect on TGF-β1-mediated PAI-1 expression. Neither TSP-1 nor TGF-β1 had an effect on uPA production. We conclude that TSP-1, in a receptor-mediated process that involves the activation of TGF-β1, upregulates PAI-1 expression in pancreatic cancer without an effect on uPA production.",
keywords = "Pancreatic neoplasms, Plasminogen activator inhibitor, Thrombospondin-1, Transforming growth factor beta-1, Urokinase plasminogen activator",
author = "Daniel Albo and Berger, {David H.} and Jon Vogel and Tuszynski, {George P.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1016/S1091-255X(99)80058-4",
language = "English (US)",
volume = "3",
pages = "411--417",
journal = "Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract",
issn = "1091-255X",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Thrombospondin-1 and Transforming Growth Factor Beta-1 Upregulate Plasminogen Activator Inhibitor Type 1 in Pancreatic Cancer

AU - Albo, Daniel

AU - Berger, David H.

AU - Vogel, Jon

AU - Tuszynski, George P.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Controlled degradation of the extracellular matrix by proteases is crucial in tumor cell invasion. We have shown that thrombospondin-1 (TSP-1), through activation of transforming growth factor beta-1 (TGF-β1), regulates the plasminogen/plasmin protease system in breast cancer. To determine whether this occurred in other epithelial neoplasms, we studied the role of TSP-1 and TGF-β1 in the regulation of the plasminogen/plasmin system in pancreatic cancer. ASPC-1 and COLO-357 pancreatic cancer cells were treated with TSP-1 or TGF-β1 at varying concentrations. The TSP-1 and TGF-β1-treated cells were also treated with either anti-TSP-1, anti-TSP-1 receptor, or anti-TGF-β1 antibodies. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) expression was determined by enzyme-linked immunosorbent assay. TSP-1 and TGF-β1 promoted a dose-dependent upregulation of ASPC-1 and COLO-357 PAI-1 expression. The TSP-1 effect could be blocked with anti-TSP-1 or anti-TGF-β1 antibodies. The TGF-β1 effect could be blocked only with anti-TGF-β1 antibody. Anti-TSP-1 receptor antibody blocked the TSP-1 effect on PAI-1 expression but had no effect on TGF-β1-mediated PAI-1 expression. Neither TSP-1 nor TGF-β1 had an effect on uPA production. We conclude that TSP-1, in a receptor-mediated process that involves the activation of TGF-β1, upregulates PAI-1 expression in pancreatic cancer without an effect on uPA production.

AB - Controlled degradation of the extracellular matrix by proteases is crucial in tumor cell invasion. We have shown that thrombospondin-1 (TSP-1), through activation of transforming growth factor beta-1 (TGF-β1), regulates the plasminogen/plasmin protease system in breast cancer. To determine whether this occurred in other epithelial neoplasms, we studied the role of TSP-1 and TGF-β1 in the regulation of the plasminogen/plasmin system in pancreatic cancer. ASPC-1 and COLO-357 pancreatic cancer cells were treated with TSP-1 or TGF-β1 at varying concentrations. The TSP-1 and TGF-β1-treated cells were also treated with either anti-TSP-1, anti-TSP-1 receptor, or anti-TGF-β1 antibodies. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) expression was determined by enzyme-linked immunosorbent assay. TSP-1 and TGF-β1 promoted a dose-dependent upregulation of ASPC-1 and COLO-357 PAI-1 expression. The TSP-1 effect could be blocked with anti-TSP-1 or anti-TGF-β1 antibodies. The TGF-β1 effect could be blocked only with anti-TGF-β1 antibody. Anti-TSP-1 receptor antibody blocked the TSP-1 effect on PAI-1 expression but had no effect on TGF-β1-mediated PAI-1 expression. Neither TSP-1 nor TGF-β1 had an effect on uPA production. We conclude that TSP-1, in a receptor-mediated process that involves the activation of TGF-β1, upregulates PAI-1 expression in pancreatic cancer without an effect on uPA production.

KW - Pancreatic neoplasms

KW - Plasminogen activator inhibitor

KW - Thrombospondin-1

KW - Transforming growth factor beta-1

KW - Urokinase plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=0033155804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033155804&partnerID=8YFLogxK

U2 - 10.1016/S1091-255X(99)80058-4

DO - 10.1016/S1091-255X(99)80058-4

M3 - Article

C2 - 10482694

AN - SCOPUS:0033155804

VL - 3

SP - 411

EP - 417

JO - Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

JF - Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

SN - 1091-255X

IS - 4

ER -